EU CE Compliance | Jinhao Pharmaceutical’s Nipah Virus Nucleic Acid Detection Kit Supports Research and Disease Prevention
发布时间：2026.02.06
Recently, a Nipah virus outbreak has occurred in West Bengal, India, posing a severe public health challenge. As a highly pathogenic zoonotic pathogen, Nipah virus disease carries a mortality rate as high as 40%–75%, making rapid detection essential for effective prevention and control.
The Nipah virus all‑in‑one premixed nucleic acid detection kit (fluorescent PCR method), developed and manufactured by Beijing Jinhao Pharmaceutical Co., Ltd., has obtained an EU CE Declaration of Conformity, meeting the requirements for market access in the European Union and providing a Chinese solution for global Nipah virus surveillance and control.
Follow us
Phone: 400-650-6787 | 010-67878866 | Address: Building 1, No. 7 Yuncheng Street, Beijing Economic-Technological Development Area, Beijing |
© 2026 Beijing Jinhao Pharmaceutical Co., Ltd. All rights reserved | Beijing ICP Filing No. 17020135-2